Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8252W HIGH $3.79
Volume
204.86 K
Value Traded
1.36 M
Short % Float
12.73%
-3.47%Week
-27.98%1 Month
-15.24%3 Month
+0.72%6 Month
-99.89%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.75 M
EPS (TTM)
-2.59
P/E Ratio
-
Ent. Value
2.77 M
Total Shares
8.45 M
Float Shares
8.22 M
Insiders
3.63%
Institutions
25.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BIVI Catalyst Timeline
Dated clinical, regulatory and corporate events for BioVie Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioVie Inc.
312Total events
5Upcoming
66Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutbezisterimClinical Data
BioVie announces topline results from Phase 2 ADDRESS-LC trial of bezisterim in Long COVID
Long COVIDsource ↗
▲Primary Endpoint MetbezisterimClinical Data
Statistically significant improvements in pre-specified high-symptom-burden subgroups
Long COVIDsource ↗
▲Safety Data UpdatebezisterimClinical Data
Bezisterim safety and tolerability similar to placebo in ADDRESS-LC
Long COVIDsource ↗
●Oral PresentationbezisterimPresentation
Conference call to discuss ADDRESS-LC topline results
Long COVIDsource ↗
▲Subgroup AnalysisbezisterimClinical Data
Pre-specified subgroup analyses show statistically significant improvements in high symptom burden patients
Long COVIDsource ↗
◆End Of Phase 2 MeetingbezisterimFDA Meeting
End-of-Phase 2 Meeting requested with FDA
Parkinson's diseasesource ↗
◆Topline ReadoutbezisterimClinical Data
Topline results for ADDRESS-LC anticipated before end of September 2026
Long COVIDsource ↗
◆End Of Phase 2 MeetingbezisterimFDA Meeting
BioVie requests End-of-Phase 2 Meeting with FDA for bezisterim in Parkinson's disease
Parkinson's diseasesource ↗
◆Topline ReadoutbezisterimClinical Data
Topline data expected from ADDRESS-LC trial
Long COVIDsource ↗
▲Topline ReadoutbezisterimClinical Data
Topline results of Phase 2 SUNRISE-PD trial announced
early-stage Parkinson's diseasesource ↗
◆Topline ReadoutbezisterimClinical Data
ADDRESS-LC topline data in Long COVID expected late summer 2026
Long COVIDsource ↗
▲Last Patient Last VisitbezisterimTrial
Last patient evaluation visit completed for SUNRISE-PD Phase 2 trial
early-stage Parkinson's diseasesource ↗
◆Oral PresentationbezisterimPresentation
Virtual KOL event to discuss Phase 2 study of bezisterim for Parkinson's disease
Parkinson's diseasesource ↗
◆Poster PresentationbezisterimPresentation
Abstract accepted for poster presentation at AAN 2026 on SUNRISE-PD baseline demographics
Parkinson's Diseasesource ↗
◆Topline ReadoutbezisterimClinical Data
Topline data from Phase 2 SUNRISE-PD trial of bezisterim for Parkinson's disease
Parkinson's diseasesource ↗
◆Poster PresentationbezisterimPresentation
Abstract accepted for poster presentation at AD/PD 2026
Parkinson's Diseasesource ↗
▲Enrollment CompletebezisterimTrial
SUNRISE-PD completed enrollment of 60 patients
Parkinson's Diseasesource ↗
◆Poster PresentationbezisterimPresentation
Poster presentation on bezisterim-associated anti-inflammatory epigenetic modulation in Alzheimer's Disease at ACP 2026
Alzheimer's Diseasesource ↗
▲Enrollment CompletebezisterimTrial
Completed enrollment of 60 patients in Phase 2 SUNRISE-PD trial
early-stage Parkinson's diseasesource ↗
◆Topline ReadoutbezisterimClinical Data
Topline data from SUNRISE-PD trial anticipated
Parkinson's diseasesource ↗
◆Trial InitiationbezisterimTrial
Phase 3 AD trial initiation with new once-daily formulation
Alzheimer's Diseasesource ↗
●Poster PresentationbezisterimPresentation
Poster presentation of ADDRESS-LC Phase 2 trial design at Keystone Symposia
Long COVIDsource ↗
●Oral PresentationbezisterimPresentation
Oral presentation of ADDRESS-LC Phase 2 trial design at Keystone Symposia
Long COVIDsource ↗
●Enrollment UpdatebezisterimTrial
Currently enrolling patients in SUNRISE-PD trial
Parkinson's Diseasesource ↗
▲Management ChangeCorporate
Appointment of Amy Chappell and Kameel Farag to Board of Directors
▲Oral PresentationbezisterimPresentation
Presented promising data on bezisterim at 7th World Aging and Rejuvenation Conference
aging and neurodegenerationsource ↗
▲Oral PresentationbezisterimPresentation
Presented data on bezisterim decreasing biological age acceleration in AD at WCAG-2025
Alzheimer's Diseasesource ↗
◆Oral PresentationbezisterimPresentation
Bezisterim Epigenetic Effects on Aging and Neurodegeneration presented at ARC-2025
Alzheimer's Diseasesource ↗
◆Enrollment UpdatebezisterimTrial
Currently enrolling patients in SUNRISE-PD trial
Parkinson's Diseasesource ↗
◆Poster PresentationbezisterimPresentation
Poster presentation of SUNRISE-PD trial design and patient experience at Advanced Therapeutics in Movement & Related Disorders Congress
Parkinson's diseasesource ↗
◆Oral PresentationbezisterimPresentation
Virtual KOL event to discuss Phase 2 study of bezisterim for Parkinson's disease
Parkinson's diseasesource ↗
▲First Patient DosedbezisterimTrial
First patient enrolled in Phase 2 ADDRESS-LC trial of bezisterim for long COVID neurological symptoms
long COVIDsource ↗
◆Poster PresentationbezisterimPresentation
Poster presentation on rationale and design of Phase 2 SUNRISE-PD trial at IAPRD 2025
Parkinson's diseasesource ↗
◆Enrollment UpdatebezisterimTrial
Currently enrolling patients in Phase 2 SUNRISE-PD trial
Parkinson's diseasesource ↗
▲Enrollment UpdatebezisterimTrial
Currently enrolling patients in Phase 2 SUNRISE-PD trial
Parkinson's diseasesource ↗
▲Trial InitiationbezisterimTrial
Recently began enrollment in Phase 2 ADDRESS-LC study
long COVIDsource ↗
◆Full ResultsbezisterimClinical Data
Reported efficacy data from Phase 3 study in mild-to-moderate Alzheimer's
Alzheimer's diseasesource ↗
▲First Patient DosedbezisterimTrial
First patient enrolled in SUNRISE-PD Phase 2 trial of bezisterim in early Parkinson's disease
Parkinson's diseasesource ↗
◆R&D DayPresentation
KOL investor webcast on long COVID treatment landscape and ADDRESS-LC trial
long COVIDsource ↗
Past FDA Catalysts and PDUFA Decisions
How BIVI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-15 | bezisterim (NE3107) | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 78%
Micro Cap(rank 515 of 660)
Percentile Rank
BioVie Inc. faces pipeline headwinds (26/100), with $429M risk-adjusted pipeline value, led by NE3107 in Alzheimer Disease (Phase 3), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NE3107 Small moleculeCompletedNCT05227820 | Alzheimer Disease | Phase 3 | COMPLETED | 462 | Aug 20, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every BIVI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| bezisterim | Long COVID | Phase 2 | 2026-09-15 | 21 out of 22 endpoints showing favorable trendsRead More | BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Palumbo Joseph MOfficer (Chief Medical Officer) | Buy | 4,843 6,036 held | $2.16 | 08/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BIVI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.2 % (-33.3 %) | 1.56 M | 457.35 K | 1.96% ( 8.79 K) |
BIVI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIVI ranks across every disease it competes in
Competitive Position is a premium feature
See how BIVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIVI News
BIVI▼ -14.6%on this news
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie announced positive topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID. The trial demonstrated significant benefits in patients with high baseline symptom burden, with 21 out of 22 endpoints showing favorable trends. Bezisterim's safety profile was comparable to placebo, and the findings suggest potential for further development in a Phase 3 trial.
Read more →BIVI▼ -14.6%on this newsshared move
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
BioVie Inc. will host a conference call on September 15, 2026, to discuss topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID. The trial aims to assess the drug's efficacy in reducing cognitive impairment and fatigue. Guest speakers include a trial investigator and a patient advocate, with a Q&A session to follow. The study is funded by a $13.13 million grant from the U.S. Department of War.
Read more →BIVIBioVie Announces Update to Parkinson’s Phase 3 Development Program
BioVie Inc. has announced the next steps in its Phase 3 development program for bezisterim, targeting Parkinson's disease. The trial will focus on both motor and non-motor symptoms, with MDS-UPDRS 1 Part III as the primary endpoint. Phase 2 data suggest significant benefits for patients with elevated inflammation. The company is seeking FDA feedback on the trial design.
Read more →BIVI▲ +5.6%on this news
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has completed the treatment phase of its ADDRESS-LC Phase 2 trial, which evaluates bezisterim for neurological symptoms associated with Long COVID. The trial, funded by the U.S. Department of War, aims to assess the drug's efficacy in improving cognitive function and reducing fatigue. Topline results are expected by the end of September 2026.
Read more →BIVI▼ -33.8%on this news· ran to -51% by day 1
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
BioVie announced positive topline results from its Phase 2 SUNRISE-PD trial for bezisterim in early Parkinson's disease. The trial demonstrated significant improvements in both motor and non-motor symptoms compared to placebo, alongside beneficial effects on biomarkers of neurodegeneration and inflammation. The results suggest bezisterim may provide a new therapeutic approach targeting the underlying biology of Parkinson's disease.
Read more →BIVIJoin BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
BioVie Inc. is hosting a live investor webinar on June 2, 2026, featuring CEO Cuong Do. The presentation will cover bezisterim, an investigational drug for neuroinflammation, and BIV201, a late-stage candidate for liver disease. The event will include a Q&A session, highlighting BioVie's progress and market opportunities.
Read more →BIVI▼ -5.3%on this newsshared move
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has announced the full enrollment of its ADDRESS-LC Phase 2 trial, which evaluates bezisterim for treating neurological symptoms associated with Long COVID. The study is fully funded by a U.S. Department of War grant and aims to assess the drug's efficacy in alleviating cognitive impairment and fatigue. Topline data is expected to be released in late summer 2026.
Read more →BIVIBioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
BioVie Inc. has completed the last patient evaluation visit for its Phase 2 SUNRISE-PD trial, which assesses the drug bezisterim in early-stage Parkinson's disease. The trial aimed to evaluate motor and non-motor endpoints and will now enter the closeout phase, with topline results anticipated in Q3 2026. The study utilized a hybrid decentralized design to enhance patient participation.
Read more →BIVI▲ +6%on this news
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie Inc. will host a virtual KOL event on May 7, 2026, to discuss the Phase 2 study of bezisterim for Parkinson's disease. The event will feature Dr. Suzanne de la Monte, who will elaborate on bezisterim's mechanism of action. The drug has shown promise in improving motor control in patients and is being evaluated for its potential benefits in neurodegenerative diseases.
Read more →BIVI▲ +5.8%on this news
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
BioVie Inc. announced that an abstract from its SUNRISE-PD study on bezisterim has been accepted for presentation at the 2026 American Academy of Neurology Annual Meeting. The abstract will summarize initial data on patients with Parkinson's Disease and will be presented during a session focused on emerging therapeutics. Topline results from the study are anticipated in mid-2026.
Read more →BIVIBioVie Announces Abstract Accepted for Presentation at AD/PD 2026
BioVie Inc. announced that its abstract on bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 conference in Copenhagen. The abstract summarizes initial data from the SUNRISE-PD study, which evaluates bezisterim's efficacy in early Parkinson's patients. Topline results are anticipated in mid-2026, highlighting the company's ongoing research in neurodegenerative diseases.
Read more →BIVIJoin Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
BioVie Inc. is inviting investors to a webinar on March 4, 2026, featuring CEO Cuong Do. The session will cover the investigational drug bezisterim, which targets neuroinflammation and insulin resistance, and the orphan drug BIV201 for liver disease. The company is advancing multiple clinical programs with potential late-stage developments.
Read more →BIVIBioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
BioVie Inc. announced the acceptance of two abstracts for its lead candidate, bezisterim, at the 2026 American College of Psychiatrists annual meeting. The abstracts focus on bezisterim's effects on Alzheimer's disease and Long COVID. The company has seen promising results in previous trials for Parkinson's disease and continues to explore bezisterim's therapeutic potential.
Read more →BIVIBioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
BioVie Inc. has successfully completed the enrollment of 60 participants in its Phase 2 SUNRISE-PD clinical trial, which is assessing the efficacy of bezisterim for early Parkinson's disease. This study focuses on individuals who have not previously received treatment with carbidopa/levodopa, utilizing a hybrid trial design to improve patient access. With topline results expected in the first half of 2026, the trial aims to explore how bezisterim may influence the progression of Parkinson's symptoms. The company's efforts were supported by prominent advocacy organizations in the Parkinson's community.
Read more →BIVIBioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host a live investor webinar on October 8, 2025, to discuss its innovative drug therapies for neurological diseases. CEO Cuong Do will present findings on bezisterim, which shows promise in treating Alzheimer’s and Parkinson’s diseases. The session will also cover BIV201, an orphan drug candidate for liver cirrhosis. A Q&A will follow the presentation.
Read more →BIVIBioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Inc. announced the presentation of its ADDRESS-LC Phase 2 trial design at the Keystone Symposia. The trial evaluates bezisterim's efficacy in treating neurological symptoms of Long COVID, a condition affecting millions. The study is fully funded by the U.S. Department of Defense and aims to address significant unmet medical needs.
Read more →BIVI▼ -6.7%on this newsshared move
BioVie Inc. Announces Closing of $12 Million Public Offering
BioVie Inc. has successfully closed a $12 million public offering, selling 6 million units at $2.00 each. The offering included warrants that are now listed on the Nasdaq Capital Market. The funds raised will be utilized for working capital and general corporate purposes. The company is focused on developing therapies for chronic conditions, including liver disease and neurodegenerative disorders.
Read more →BIVI▼ -42.6%on this newsshared move
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. has announced the pricing of its $12 million public offering, which includes 6,000,000 units priced at $2.00 each. The offering is set to close on August 11, 2025, and proceeds will be used for working capital and general corporate purposes. The warrants included in the offering are expected to trade on the Nasdaq Capital Market.
Read more →BIVI▼ -8.4%on this news
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
BioVie Inc. presented findings at the 2nd World Conference on Aging and Gerontology, indicating that bezisterim may decelerate biological aging in Alzheimer's patients compared to placebo. The drug targets inflammation and has shown promise in improving healthspan. Ongoing studies aim to further explore its efficacy in Alzheimer's and other neurodegenerative diseases.
Read more →About BioVie Inc.
Headquarters680 W NYE LANE, CARSON CITY, NV, 89703
BIOPHARMAWATCH ELITE PLUS
Trade the next BIVI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime